The Discounted Cash Flow (DCF) valuation of Newron Pharmaceuticals SpA (NWRN.SW) is (23.70) CHF. With the latest stock price at 7.70 CHF, the upside of Newron Pharmaceuticals SpA based on DCF is -407.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.1% - 6.5% | 5.3% |
| Long-term Growth Rate | 3.0% - 3.9% | 3.4% |
| Fair Price | (160.24) - (13.81) | (23.70) |
| Upside | -2181.0% - -279.3% | -407.7% |